174 related articles for article (PubMed ID: 7559191)
41. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration].
Alvarado D; Díaz MC; Silva V
Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107
[TBL] [Abstract][Full Text] [Related]
42. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
Quereda C; Polanco AM; Giner C; Sánchez-Sousa A; Pereira E; Navas E; Fortún J; Guerrero A; Baquero F
Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):30-7. PubMed ID: 8641300
[TBL] [Abstract][Full Text] [Related]
43. In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.
Hundt W; Hofmann H
Infection; 1994; 22(2):124-31. PubMed ID: 8070926
[TBL] [Abstract][Full Text] [Related]
44. Influence of human serum on antifungal pharmacodynamics with Candida albicans.
Zhanel GG; Saunders DG; Hoban DJ; Karlowsky JA
Antimicrob Agents Chemother; 2001 Jul; 45(7):2018-22. PubMed ID: 11408217
[TBL] [Abstract][Full Text] [Related]
45. Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.
Redding SW; Pfaller MA; Messer SA; Smith JA; Prows J; Bradley LL; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1997 Jul; 35(7):1761-5. PubMed ID: 9196188
[TBL] [Abstract][Full Text] [Related]
46. Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.
Pinjon E; Jackson CJ; Kelly SL; Sanglard D; Moran G; Coleman DC; Sullivan DJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1312-8. PubMed ID: 15793103
[TBL] [Abstract][Full Text] [Related]
47. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.
Arikan S; Akova M; Hayran M; Ozdemir O; Erman M; Gür D; Unal S
Clin Infect Dis; 1998 Apr; 26(4):903-8. PubMed ID: 9564473
[TBL] [Abstract][Full Text] [Related]
48. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
49. Improved medium for fluconazole susceptibility testing of Candida albicans.
Rodriguez-Tudela JL; Martinez-Suarez JV
Antimicrob Agents Chemother; 1994 Jan; 38(1):45-8. PubMed ID: 8141578
[TBL] [Abstract][Full Text] [Related]
50. [Antifungal susceptibility testing of commensal and pathogenic clinical isolates of oral Candida].
Zhao M; Zhou ZT
Shanghai Kou Qiang Yi Xue; 2006 Apr; 15(2):218-20. PubMed ID: 16685371
[TBL] [Abstract][Full Text] [Related]
51. Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Siikala E; Rautemaa R; Richardson M; Saxen H; Bowyer P; Sanglard D
J Antimicrob Chemother; 2010 Dec; 65(12):2505-13. PubMed ID: 20876623
[TBL] [Abstract][Full Text] [Related]
52. [Treatment and secondary prophylaxis with fluconazole for oropharyngeal candidiasis in HIV-positive patients. A mycological analysis of failures].
Reynes J; Mallié M; André D; Janbon F; Bastide JM
Pathol Biol (Paris); 1992 May; 40(5):513-7. PubMed ID: 1495836
[TBL] [Abstract][Full Text] [Related]
53. Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.
Barchiesi F; Najvar LK; Luther MF; Scalise G; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1996 May; 40(5):1317-20. PubMed ID: 8723495
[TBL] [Abstract][Full Text] [Related]
54. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
[TBL] [Abstract][Full Text] [Related]
55. Neutrophil phagocytosis in AIDS patients with azole resistant candidiasis.
Diz Dios P; Iglesias I; Valcarcel JP; Ocampo A; Vazquez E; Castro M
Oral Dis; 1997 May; 3 Suppl 1():S113-5. PubMed ID: 9456669
[TBL] [Abstract][Full Text] [Related]
56. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation.
Gallagher PJ; Bennett DE; Henman MC; Russell RJ; Flint SR; Shanley DB; Coleman DC
J Gen Microbiol; 1992 Sep; 138(9):1901-11. PubMed ID: 1402791
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.
Perea S; López-Ribot JL; Kirkpatrick WR; McAtee RK; Santillán RA; Martínez M; Calabrese D; Sanglard D; Patterson TF
Antimicrob Agents Chemother; 2001 Oct; 45(10):2676-84. PubMed ID: 11557454
[TBL] [Abstract][Full Text] [Related]
58. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.
Arthington-Skaggs BA; Warnock DW; Morrison CJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2081-5. PubMed ID: 10898679
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis.
Salari S; Khosravi AR; Mousavi SA; Nikbakht-Brojeni GH
J Mycol Med; 2016 Mar; 26(1):35-41. PubMed ID: 26627124
[TBL] [Abstract][Full Text] [Related]
60. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.
Rex JH; Pfaller MA; Galgiani JN; Bartlett MS; Espinel-Ingroff A; Ghannoum MA; Lancaster M; Odds FC; Rinaldi MG; Walsh TJ; Barry AL
Clin Infect Dis; 1997 Feb; 24(2):235-47. PubMed ID: 9114154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
